Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI112 in Moderate-to-Severe Active Ulcerative Colitis (Phase II, randomized, double-blind, placebo-controlled)
CTR20221017Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of picankibart in autoimmune colitis, sponsored by InnoCare Pharma. Started Apr 2022; status: completed.
02
Drugs
picankibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20221017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221017.